Autori: Alessandro Busca, Franco Locatelli, Simona Emilia Flonta, Gianni Ciccone, Ileana Baldi, Stefano D'Ardia, Bernardino Allione and Michele Falda
Editorial: Am J Hematol , 86(2):, p.214-217 , 2011.
Graft versus host disease (GVHD) represents one of the major limiting factors to the successful applicability of hematopoietic stem cells transplantation (HSCT). In particular, allogeneic HSCT from alternative donors with unmanipulated graft results in an increased risk of both acute and chronic GVHD compared with matched sibling donor transplants . At the present, none of the GVHD prophylactic strategies currently in use, including calcineurin inhibitors , T-lymphocyte depletion, and monoclonal antibodies [3,4], have been proven to be of superior efficacy over another.
Cuvinte cheie: GvHD, antithymocyte globulin, allogeneic hematopoietic stem cell transplantation